Companies such as AbbVie Inc. (U.S.), Pfizer Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Novartis AG (Switzerland), and GlaxoSmithKline plc (U.K.) are major players in the Hidradenitis Suppurativa Treatment market.
In January 2025, Roche announced positive Phase III trial results for a new bispecific antibody targeting cervical tumor microenvironment, showing a 27% improvement in progression-free survival over standard care.
The countries covered in the global hidradenitis suppurativa treatment market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, and rest of Middle East and Africa.
Corporate Email ID Only (Avoid Using Generic mail ID such as Gmail)
Consent Preferences
We use cookies to improve your experience We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site, or closing this box, you consent to our use of cookies. Cookie Notice.
The data presented is for visualization purposes only and may not reflect actual results.